A Phase 3 interventional study of VDPHL01 QD and Placebo in Androgenetic Alopecia (AGA), Androgenetic Alopecia and AGA, sponsored by Veradermics, Inc.. Active, not recruiting at 71 sites in United States. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Veradermics, Inc. · Phase 3, Interventional, and Treatment
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA).
AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA.
This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Not required.
609 studies on the registry are indexed under Alopecia; 131 are open to participants now.
This study's planned enrollment of 552 is above the median of 45 across 513 interventional studies indexed under Alopecia.
Browse Alopecia studies →Veradermics, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Use of any of the following treatments within the indicated washout period before screening:
VDPHL01 will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will continue VDPHL01 BID for an additional 6 months.
Drug: VDPHL01 BID
Placebo will be taken orally once a day (QD) in the AM or PM. VDPHL01 will be taken orally once a day (QD) in the AM or PM for the first 6 months of the study. After month 6, subject will continue this same dose regimen for an additional 6 months.
Drug: VDPHL01 QD · Drug: Placebo
Placebo will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will switch to VDPHL01 BID group, and take VDPHL01 orally twice a day (BID), once in the AM and once in the PM for an additional 6 months.
Drug: Placebo
Placebo will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will switch to VDPHL01 QD and Placebo QD group, and take placebo orally once a day in the AM or PM; VDPHL01 will be taken orally once a day in the AM or PM for an additional 6 months.
Drug: Placebo
VDPHL01 Extended Release (ER) Tablet
Placebo tablet
VDPHL01 Extended Release (ER) Tablet
Placebo tablet
Changes in non-vellus Target Area Hair Counts (TAHC)
Changes from baseline in non-vellus TAHC using digital image analysis at Month 6.
Time frame: Month 6
Subjects Evaluation of Treatment Benefit
Subjects will rate their treatment benefit by responding to a hair assessment scale. The proportion of subjects by each response category will be reported at Month 6.
Time frame: Month 6
Plan to share: Undecided — The sponsor is undecided if this information will be shared at this time. This field will be updated when a decision is made.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Veradermics, Inc.